IONS logo

IONS
Ionis Pharmaceuticals Inc

6,619
Mkt Cap
$11.99B
Volume
680,555.00
52W High
$76.78
52W Low
$23.95
PE Ratio
-43.24
IONS Fundamentals
Price
$74.58
Prev Close
$74.00
Open
$74.25
50D MA
$69.25
Beta
0.70
Avg. Volume
2.11M
EPS (Annual)
-$3.04
P/B
19.30
Rev/Employee
$659,623.95
Loading...
Loading...
News
all
press releases
Savant Capital LLC Acquires Shares of 5,607 Ionis Pharmaceuticals, Inc. $IONS
Savant Capital LLC bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the second quarter, according to the company in its most recent filing with the...
MarketBeat·7h ago
News Placeholder
More News
News Placeholder
Ionis Pharmaceuticals, Inc. $IONS Stock Holdings Increased by Raiffeisen Bank International AG
Raiffeisen Bank International AG raised its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 35.9% during the 2nd quarter, according to its most recent disclosure with...
MarketBeat·1d ago
News Placeholder
Candriam S.C.A. Has $28.64 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
Candriam S.C.A. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 27.1% during the 2nd quarter, according to the company in its most recent 13F filing...
MarketBeat·5d ago
News Placeholder
Ionis Pharmaceuticals (NASDAQ:IONS) Sees Strong Trading Volume - Still a Buy?
Ionis Pharmaceuticals (NASDAQ:IONS) Sees Unusually-High Trading Volume - What's Next...
MarketBeat·6d ago
News Placeholder
DAWNZERA (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Business Wire·6d ago
News Placeholder
Fox Run Management L.L.C. Takes $434,000 Position in Ionis Pharmaceuticals, Inc. $IONS
Fox Run Management L.L.C. acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the second quarter, according to the company in its most recent filing with...
MarketBeat·6d ago
News Placeholder
Leerink Partnrs Has Pessimistic View of IONS FY2027 Earnings
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2027 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a report...
MarketBeat·7d ago
News Placeholder
Vestmark Advisory Solutions Inc. Invests $567,000 in Ionis Pharmaceuticals, Inc. $IONS
Vestmark Advisory Solutions Inc. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·7d ago
News Placeholder
Profund Advisors LLC Sells 6,028 Shares of Ionis Pharmaceuticals, Inc. $IONS
Profund Advisors LLC decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 17.3% in the second quarter, according to its most recent Form 13F filing with the...
MarketBeat·7d ago
News Placeholder
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $700.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the notes) in a private placement (the...
Business Wire·7d ago

Latest IONS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.